Research and Development

The projected rate of return on pharma industry research and development has more than halved since 2010, from 10.1% to …

AstraZeneca and Takeda have agreed a multi-million pound deal for AZ to acquire the Japanese firm’s core respiratory business, including …

With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster …

Proposed Government changes to legislation will require businesses to track and trace all R&D expenditure if they want to continue …

The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …

Precious Cells Group, a UK-based international provider of stem cell storage and related technologies, has announced the appointment of commercial …

Amgen has announced that it will reacquire the rights to three products in 48 countries from GSK, as it seeks …

Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …

Drug development companies should prioritise strategic pharma collaborations to keep up with the next wave of immuno-oncology treatments, the chief …

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …

It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …

MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …